Acrivon Therapeutics (ACRV) director Sharon Shacham awarded 20,275 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Acrivon Therapeutics, Inc. director Sharon Shacham received a grant of stock options representing 20,275 shares of common stock. The options have an exercise price of $1.52 per share and expire on June 16, 2036.
All 20,275 option shares remain held following the transaction. According to the grant terms, these options vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, provided Shacham continues to serve through that vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Shacham Sharon
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,275 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,275 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 20,275 options
Exercise price: $1.52 per share
Expiration date: June 16, 2036
+2 more
5 metrics
Options granted
20,275 options
Stock Option (Right to Buy) grant to director Sharon Shacham
Exercise price
$1.52 per share
Exercise price of options on Acrivon common stock
Expiration date
June 16, 2036
Option expiration for 20,275-share grant
Shares underlying options
20,275 shares
Underlying Acrivon common stock tied to option grant
Total options held after grant
20,275 options
Total derivative securities following this transaction
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, derivative security, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.5200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-16T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative security financial
"transaction_type: "derivative""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"options shall vest on the date immediately preceding the date of the Issuer's next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did Acrivon Therapeutics (ACRV) director Sharon Shacham report on this Form 4?
Sharon Shacham reported receiving a grant of stock options for 20,275 shares of Acrivon Therapeutics common stock. These options were awarded as compensation and are documented as a derivative security labeled “Stock Option (Right to Buy)” tied to the company’s common stock.
What are the key terms of Sharon Shacham’s ACRV stock option grant?
The grant covers 20,275 underlying shares at an exercise price of $1.52 per share, expiring on June 16, 2036. All 20,275 options are held directly following the transaction, reflecting a compensation-related award rather than an open-market stock purchase or sale.
When do Sharon Shacham’s Acrivon Therapeutics options vest?
The options vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditional on Sharon Shacham’s continuous service with the company through that vesting date, as specified in the footnote to the Form 4 filing.